Elevation Oncology, Inc. (NASDAQ:ELEV – Get Free Report) saw a significant decrease in short interest in November. As of November 30th, there was short interest totalling 593,500 shares, a decrease of 10.8% from the November 15th total of 665,100 shares. Approximately 1.8% of the company’s shares are short sold. Based on an average trading volume […]
Elevation Oncology, Inc. (NASDAQ:ELEV – Get Free Report) was the recipient of a large decline in short interest in the month of November. As of November 30th, there was short interest totalling 593,500 shares, a decline of 10.8% from the November 15th total of 665,100 shares. Based on an average daily trading volume, of 218,500 […]
Caxton Corp decreased its holdings in shares of Elevation Oncology, Inc. (NASDAQ:ELEV – Free Report) by 68.2% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 21,725 shares of the company’s stock after selling 46,599 shares during the period. Elevation Oncology makes up approximately 0.1% of […]
Wedbush reiterated their outperform rating on shares of Elevation Oncology (NASDAQ:ELEV – Free Report) in a research report report published on Monday morning, Benzinga reports. They currently have a $5.00 price objective on the stock. Wedbush also issued estimates for Elevation Oncology’s Q4 2023 earnings at ($0.26) EPS, FY2023 earnings at ($1.21) EPS, Q1 2024 […]
HC Wainwright initiated coverage on shares of Elevation Oncology (NASDAQ:ELEV – Free Report) in a research report sent to investors on Friday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $1.50 target price on the stock. Elevation Oncology Stock Up 1.9 % ELEV opened at $0.68 on Friday. The firm has […]